Clay Siegall, PhD. co-founded Seattle Genetics, a biotech company that focuses on developing antibody-drug conjugates that are used to treat various forms of cancer. Clay serves as the company’s President, Chief Executive Officer and Chairman of the Board of Directors. The company started in 1998 and has been making headways into the treatment of cancer and autoimmune diseases.
Seattle Genetics is working together with Takeda Pharmaceutical Company, to get Siegall’s ADCETRIS approved in over 60 countries. Siegall has been behind the public offerings that have raised a total of $1.2 billion in assets for the company. Dr. Siegall earned his PhD. in Genetics from George Washington University. He worked with the National Institutes of Health from 1988 to 1991. He was with Bristol-Myers Squibb Pharmaceutical Research from 1991 to 1997.
Currently, Siegall serves on the Board of Ultragenyx Pharmaceutical, the Washington Round Table and Alder BioPharmaceuticals. He has received several awards for his work in the industry, including 2013 Computer, Math and Natural Sciences award and 2012 Pacific Northwest Ernst and Young Entrepreneur of the Year Award. Clay has written articles for over 70 publications and he holds 15 patents.
Seattle Genetics has built a solid reputation around the values of integrity, excellence in the development of scientific products, teamwork and innovative respect for each other. These principals promote the individual efforts of team members in developing breakthrough therapies at the company.
The company is committed to doing business in the most ethical way possible. They are compliant with healthcare laws and rules governing the industry. Always being compliant builds trust with patience and healthcare professionals.